The purpose of this study was to investigate the expression of long non-coding RNA (lncRNA)-SChLAP1 in breast cancer (BCa) tissues and its clinical significance in the progression of this cancer. 100 pairs of surgically resected BCa tissue samples and normal breast tissues were collected from BCa patients, and SChLAP1 expression in above tissues was detected by quantitative real-time polymerase chain reaction (qRT-PCR). Meanwhile, the receiver operating curve (ROC) was plotted to analyze the efficacy of SChLAP1 in the diagnosis of BCa. https://www.selleckchem.com/products/liraglutide.html In addition, the interplay between SChLAP1 expression and clinical features as well as the pathological features of BCa patients was analyzed. The expression level of SChLAP1 in BCa tissue samples was remarkably higher than that in normal ones. When the area under the ROC curve (AUC)=0.8639 and p<0.001, BCa could be diagnosed by SChLAP1; meanwhile, when the cut-off value was 3.26, the sensitivity was 80% and the specificity was 72%. Moreover, it was uncovered that the SChLAP1 expression was associated with patients' menarche, menopause, age of first pregnancy, or whether breastfeeding is administrated and whether oral contraceptives is taken; in addition, alcohol consumption, body mass index or tumor size and clinical stage were also the factors affecting the expression of SChLAP1. SChLAP1 is highly expressed in BCa tissues and can serve as a potential biomarker for the diagnosis of this cancer. SChLAP1 is highly expressed in BCa tissues and can serve as a potential biomarker for the diagnosis of this cancer. Sentinel lymph node biopsy (SLNB) is an invasive surgical procedure and although it has fewer complications and is less severe than axillary lymph node dissection, it is not a risk-free procedure. Large prospective trials have documented SLNB that it is considered non-therapeutic in early stage breast cancer. Web-calculator CancerMath (CM) allows you to estimate the probability of having positive lymph nodes valued on the basis of tumour size, age, histologic type, grading, expression of estrogen receptor, progesterone receptor. We collected 595 patients referred to our Institute resulting clinically negative T1 breast cancer characterized by sentinel lymph node status, prognostic factors defined by CM and also HER2 and Ki-67. We have compared classification performances obtained by online CM application with those obtained after training its algorithm on our database. By training CM model on our dataset and using the same feature, adding HER2 or ki67 we reached a sensitivity median value of 71.4%, 73%, 70.4%, respectively, whereas the online one was equal to 61%, without losing specificity. The introduction of the prognostic factors Her2 and Ki67 could help improving performances on the classification of particularly type of patients. Although the training of the model on the sample of T1 patients has brought a significant improvement in performance, the general performance does not yet allow a clinical application of the algorithm. However, the experimental results encourage future developments aimed at introducing features of a different nature in the CM model. Although the training of the model on the sample of T1 patients has brought a significant improvement in performance, the general performance does not yet allow a clinical application of the algorithm. However, the experimental results encourage future developments aimed at introducing features of a different nature in the CM model. Early-stage, HER2-positive breast cancer is increasingly treated with neoadjuvant chemotherapy (NAC). After the positive results of the Neosphere trial, the standard of care has been the combination of chemotherapy with two anti-HER2 agents, trastuzumab and pertuzumab. Many oncologists use the sequence of four cycles of anthracycline-containing regimen followed by four cycles of taxane with the two monoclonals. We report here the cardiac safety of four cycles of epirubicin with cyclophosphamide followed by four cycles of docetaxel with trastuzumab and pertuzumab, given at the neoadjuvant setting in early, HER2-positive breast cancer. We retrospectively collected data from the medical records of patients treated at our clinic between 2014 and 2020. It total, 55 patients treated with the same regimen were identified. There were 20 estrogen receptor (ER)-negative and 35 ER-positive patients. Complete pathologic response was observed in 64.8% of the patients. After a median cardiac follow-up of 2.61 years, and a total of 283 echocardiograms, there was only one recorded asymptomatic Left Ventricular Ejection Fraction (LVEF) fall > 25% and no symptomatic left ventricular systolic dysfunction. LVEF consistently dropped during treatment, but the drop was not significant enough to necessitate treatment interruption, and improved during follow-up. Our data confirm the effectiveness and cardiac safety of the aforementioned neoadjuvant regimen. Our data confirm the effectiveness and cardiac safety of the aforementioned neoadjuvant regimen. Many cohort studies and meta-analyses support the oncogenic role of the human papilloma virus (HPV) on breast tissue. However, only a few studies examine the association between HPV-positive breast cancer and the prior history of high grade cervical intraepithelial neoplasia (CIN) or cervical cancer. The present systematic review and meta-analysis aimed to determine whether women with a history of high grade CIN or cervical cancer are at a higher risk of developing HPV-positive breast cancer. MEDLINE, CENTRAL and Scopus databases as well as "gray literature" sources were searched for case-control studies, detecting and genotyping HPV genome in breast cancer patients with and without a history of CIN or cervical cancer, from inception to October 23, 2020. The meta-analysis included three case-control studies with 265 breast cancer patients in total. HPV related breast cancer was associated with a history of high grade CIN or cervical cancer [pooled odds ratio (OR) =7.98, 95% confidence interval (CI), 1.84 to 34.67]. This association remained regarding HPV-16 related breast cancer (pooled OR =7.60, 95% CI, 1.75 to 33.00). HPV was detected more frequently in breast cancer patients with CIN or cervical cancer history. Therefore, further research is necessary to understand better the HPV transmission route to the breast. HPV was detected more frequently in breast cancer patients with CIN or cervical cancer history. Therefore, further research is necessary to understand better the HPV transmission route to the breast.